MENU
+Compare
FTXH
ETF ticker: NASDAQ
AS OF
Sep 17, 04:41 PM (EDT)
Price
$27.99
Change
+$0.16 (+0.57%)
Net Assets
15.33M

FTXH stock forecast, quote, news & analysis

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index... Show more

Category: #Health
FTXH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for FTXH with price predictions
Sep 16, 2025

FTXH's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for FTXH moved out of overbought territory on August 25, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where FTXH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on September 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FTXH as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FTXH turned negative on September 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FTXH broke above its upper Bollinger Band on September 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The 50-day moving average for FTXH moved above the 200-day moving average on September 02, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 216 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Regeneron Pharmaceuticals (NASDAQ:REGN).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF ETF is 46.49B. The market cap for tickers in the group ranges from 1.68B to 685.53B. LLY holds the highest valuation in this group at 685.53B. The lowest valued company is VCEL at 1.68B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 14%. For the same ETF, the average monthly price growth was 41%, and the average quarterly price growth was 86%. KRYS experienced the highest price growth at 9%, while AXSM experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 20%. For the same stocks of the ETF, the average monthly volume growth was 5% and the average quarterly volume growth was 10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 75
Price Growth Rating: 55
SMR Rating: 67
Profit Risk Rating: 69
Seasonality Score: -36 (-100 ... +100)
View a ticker or compare two or three
FTXH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Wheaton
Phone
N/A
Web
www.ftportfolios.com